Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Magnetic imaging agent
Reexamination Certificate
2006-08-01
2006-08-01
Weber, Jon (Department: 1653)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Magnetic imaging agent
C424S192100, C530S300000, C530S350000, C530S378000, C530S333000, C530S402000, C514S002600
Reexamination Certificate
active
07083777
ABSTRACT:
A pharmaceutical composition consisting of identical repeating units, each unit having a charge motif composed of a positively charged free amino moiety and a negatively charged moiety, wherein the positively charged free amino moiety and the negatively charged moiety of each charge motif are separated by at least one neutral amino acid, and wherein the positively charged free amino moiety of one of the charge motifs is separated by a distance of at least 8 amino acids from the positively charged amino moiety of another charge motif, and a pharmaceutically acceptable carrier. Said pharmaceutical composition is useful for inducing IL-2, activating T cells to produce a T helper 1 cytokine profile, suppressing IgG antibody response to specific antigen, promoting allograft survival, reducing postoperative surgical adhesion formation, and/or protecting against abscess formation associated with surgery, trauma or diseases that predispose the host to abscess formation.
REFERENCES:
patent: 3849550 (1974-11-01), Teitelbaum et al.
patent: 4619995 (1986-10-01), Hayes
patent: 4819617 (1989-04-01), Goldberg et al.
patent: 4886787 (1989-12-01), de Belder et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 5130417 (1992-07-01), Stanley et al.
patent: 5140016 (1992-08-01), Goldberg et al.
patent: 5196510 (1993-03-01), Rodwell et al.
patent: 5215896 (1993-06-01), Keck et al.
patent: 5514581 (1996-05-01), Ferrari et al.
patent: 5605938 (1997-02-01), Roufa et al.
patent: 5679654 (1997-10-01), Tzianabos et al.
patent: 5679658 (1997-10-01), Elson
patent: 5700787 (1997-12-01), Tzianabos et al.
patent: 5700906 (1997-12-01), Arnot et al.
patent: 5705178 (1998-01-01), Roufa et al.
patent: 5760200 (1998-06-01), Miller et al.
patent: 6150459 (2000-11-01), Mayes et al.
patent: 6447765 (2002-09-01), Horwitz
patent: 3704389 (1988-08-01), None
patent: WO 95/31990 (1995-11-01), None
patent: WO 96/07427 (1996-03-01), None
patent: WO 96/32119 (1996-10-01), None
Basu, S. et al. (1997) “synthesis and characterization of a peptide nucleic acid conjugated to a D-peptide analog of insulin-like growth factor 1 for increased cellar uptake” Bioconj. Chem. vol. 8, pp. 481-488.
Simmons, C. G. et al. (1997) “Synthesis and membrane premerbility of PNA-peptide conjugates” Biorg. Med. Chem. Lett. vol. 7, pp. 3001-3005.
Nielsen, P. (1999) “Applications of peptide nucleic acids” Curr. Opin. Biotechnol. vol. 10, pp. 71-75.
Bazan, J. F. (1992) Unraveling the structure of IL-2. Science. vol. 257, pp. :410-413.
http://www.mindfully.org/Plastic/Polymers/Polyethylene-Glycols-PEGs.htm.
Perumal VK et al.,Clinical Research38(2):550A (1990).
Kalka-Moll WM et al.,Abstracts of the 98th Gen. Mtg. of the Amer. Soc. for Microbiol.98:123 (1998).
Tzianabos A et al.,Abstracts of the 99th Gen. Mtg. of the Amer. Soc. for Microbiol.99:37-38 (1999).
PCT International Search Report for PCT/US00/08586.
Aharoni R et al., Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1.J NeuroimmunolNov. 2, 1998;91(1-2):135-46.
Aharoni R et al., Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.Proc Natl Acad Sci U S ASep. 30, 1997;94(20):10821-6.
Aharoni R et al., Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease.Immunol LettJul. 1997;58(2):79-87.
Arnon R et al., New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis.J NeurolApr. 1996;243(4 Suppl 1):S8-13.
Baumann H et al., Structural elucidation of two capsular polysaccharides from one strain ofBacteroides fragilisusing high-resolution NMR spectroscopy.BiochemistryApr. 28, 1992;31(16):4081-9.
Fridkis-Hareli M et al., Binding motifs of copolymer 1 to multiple sclerosis- and rheumatoid arthritis-associated HLA-DR molecules.J ImmunolApr. 15, 1999;162(8):4697-704.
Fridkis-Hareli M et al., Binding of random copolymers of three amino acids to class II MHC molecules.Int ImmunolMay 1999;11(5):635-41.
Fridkis-Hareli M et al., Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells—specificity and promiscuity.Proc Natl Acad Sci U S AMay 24, 1994;91(11):4872-6.
Fridkis-Hareli M et al., Synthetic copolymer 1 and myelin basic protein do not require processing prior to binding to class II major histocompatibility complex molecules on living antigen-presenting cells.Cell ImmunolJul. 1995;163(2):229-36.
Gibson FC 3rd et al., Cellular mechanism of intraabdominal abscess formation byBacteroides fragilis. J ImmunolMay 15, 1998;160(10):5000-6.
Gibson FC 3rd et al., The capsular polysaccharide complex ofBacteroides fragilisinduces cytokine production from human and murine phagocytic cells.Infect ImmunMar. 1996;64(3):1065-9.
Kalka-Moll WM et al., Effect of molecular size on the ability of zwitterionic polysaccharides to stimulate cellular immunity.J ImmunolJan. 15, 2000;164(2):719-24.
Kato T et al., Interleukin 10 reduces mortality from severe peritonitis in mice.Antimicrob Agents ChemotherJun. 1995;39(6):1336-40.
Kennedy R et al., Prevention of experimental postoperative peritoneal adhesions by N,O-carboxymethyl chitosan.SurgeryNov. 1996;120(5):866-70.
Krause TJ et al., An inhibitor of cell proliferation associated with adhesion formation is suppressed by N,O-carboxymethyl chitosan.J Invest SurgMar.-Apr. 1998;11(2):105-13.
Montz FJ et al., Interleukin-10: ability to minimize postoperative intraperitoneal adhesion formation in a murine model.Fertil SterilJun. 1994;61(6):1136-40.
Pantosti A et al.,Bacteroides fragilisstrains express multiple capsular polysaccharides.J Clin MicrobiolJul. 1993;31(7):1850-5.
Pantosti A et al., Immunochemical characterization of two surface polysaccharides ofBacteroides fragilis. Infect ImmunJun. 1991:59(6):2075-82.
Pavliak V et al., Structural elucidation of the capsular polysaccharide ofBacteroides fragilisstrain 23745M1.Carbohydr ResOct. 2, 1995;275(2):333-41.
Schlegel PG et al., A synthetic random basic copolymer with promiscuous binding to class II major histocompatibility complex molecules inhibits T-cell proliferative responses to major and minor histocompatibility antigens in vitro and confers the capacity to prevent murine graft-versus-host disease in vivo.Proc Natl Acad Sci U S AMay 14, 1996;93(10):5061-6.
Teitelbaum D et al., Immunomodulation of experimental autoimmune encephalomyelitis by oral administration of copolymer 1.Proc Natl Acad Sci U S AMar. 30, 1999;96(7):3842-7.
Teitelbaum D et al., Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1.Proc Natl Acad Sci U S ADec. 1988;85(24):9724-8.
Teitelbaum D et al., Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein.Proc Natl Acad Sci U S AJan. 1, 1992;89(1):137-41.
Teitelbaum D et al., Unprimed spleen cell populations recognize macrophage-bound antigen with opposite net electric charge.Proc Natl Acad Sci U S AApr. 1977;74(4):1693-6.
Tzianabos AO et al., Bacterial structure and functional relation to abscess formation.Infect Agents Dis1994 3:256-65.
Tzianabos AO et al., Effect of surgical adhesion reduction devices on the propagation of experimental intra-abdominal infection.Arch SurgNov. 1999;134(11):1254-9.
Tzianabos AO et al., IL-2 mediates protection against abscess formation in an experimental model of sepsis.J ImmunolJul. 15, 1999;163(2):893-7.
Tzianabos AO et al., Polysaccharide-mediated protection against abscess formation in experimental intra-abdominal sepsis.J Clin InvestDec. 1995;96(6):2727-31.
Tzianabos AO et al., Protection against experimental intraabdominal sepsis by two polysaccharide immunomodulators.J Infect DisJul. 1998;178(1):200-6.
Tzianabos AO et al., Structural characteristics of polysaccharides that induce protection against intra-abdominal abscess formation.Infect ImmunNo
Kasper Dennis L.
Onderdonk Andrew B.
Tzianabos Arthur O.
Wang Ying
Liu Samuel Wei
The Brigham and Women's Hospital, Inc.
Weber Jon
Wolf Greenfield & Sacks P.C.
LandOfFree
Immunomodulating polymers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunomodulating polymers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunomodulating polymers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3628833